I would have thought any spend on manufacturing devices that haven't been sold would have been allocated to the Balance Sheet and not to the P&L.
Unless a device has been sold it shouldn't be treated as a cost of sale or expensed (unless it it is being written off).
Perhaps there are some higher R&D costs coming through - but again I think there is some opportunity to treat these as either P&L or B/Sheet.
I was holding a small parcel as of this morning and looking at buying a fair bit more shortly. But will hold off for the moment and look a little more closely as the annual report (in August?)
- Forums
- ASX - By Stock
- BCC
- Ann: Trading Update for FY2022 and FY2023
Ann: Trading Update for FY2022 and FY2023, page-8
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
14.5¢ |
Change
-0.015(9.38%) |
Mkt cap ! $12.53M |
Open | High | Low | Value | Volume |
16.0¢ | 16.0¢ | 14.5¢ | $2.467K | 15.46K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 140000 | 14.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.0¢ | 19766 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 140000 | 0.140 |
1 | 22499 | 0.135 |
2 | 59099 | 0.110 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.160 | 19766 | 1 |
0.165 | 8000 | 1 |
0.170 | 1003 | 1 |
0.185 | 7500 | 1 |
0.190 | 20000 | 1 |
Last trade - 14.19pm 15/07/2024 (20 minute delay) ? |
Featured News
BCC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online